{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T04:15:13Z","timestamp":1727496913937},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,26]]},"DOI":"10.7759\/cureus.70290","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T05:40:42Z","timestamp":1727415642000},"source":"Crossref","is-referenced-by-count":0,"title":["Dexamethasone-Sparing Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting in Highly and Moderately Emetogenic Chemotherapy: The SHEILD Study"],"prefix":"10.7759","author":[{"given":"Sudheer","family":"Reddy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh  B","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tirumala","family":"Venkatesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uday","family":"Kumar Punukollu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suyash B","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richa","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.ijmr_1821_22","article-title":"Cancer incidence estimates for 2022 & projection for 2025: Result from National Cancer Registry Programme, India","volume":"156","author":"Sathishkumar K","year":"2022","unstructured":"Sathishkumar K, Chaturvedi M, Das P, Stephen S, Mathur P. Cancer incidence estimates for 2022 & projection for 2025: Result from National Cancer Registry Programme, India. Indian J Med Res. 2022, 156:598-607. 10.4103\/ijmr.ijmr_1821_22","journal-title":"Indian J Med Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2020.100278","article-title":"Chemotherapy-induced nausea and vomiting: Pathogenesis, recommendations, and new trends","volume":"26","author":"Gupta K","year":"2021","unstructured":"Gupta K, Walton R, Kataria SP. Chemotherapy-induced nausea and vomiting: Pathogenesis, recommendations, and new trends. Cancer Treat Res Commun. 2021, 26:100278. 10.1016\/j.ctarc.2020.100278","journal-title":"Cancer Treat Res Commun"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.2016.006023","article-title":"Survey of implementation of antiemetic prescription standards in Indian oncology practices and its Adherence to the American society of clinical oncology antiemetic clinical guideline","volume":"3","author":"Patil V","year":"2017","unstructured":"Patil V, Noronha V, Joshi A, et al.. Survey of implementation of antiemetic prescription standards in Indian oncology practices and its Adherence to the American society of clinical oncology antiemetic clinical guideline. J Glob Oncol. 2017, 3:346-59. 10.1200\/JGO.2016.006023","journal-title":"J Glob Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S76158","article-title":"Profile of netupitant\/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)","volume":"9","author":"Navari RM","year":"2015","unstructured":"Navari RM. Profile of netupitant\/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Des Devel Ther. 2015, 9:155-61. 10.2147\/DDDT.S76158","journal-title":"Drug Des Devel Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30210","article-title":"Addressing adherence to guidelines on prevention of acute chemotherapy-induced nausea and vomiting in pediatric patients","volume":"70","author":"Kacar M","year":"2023","unstructured":"Kacar M, MacDonald P, Gibson P. Addressing adherence to guidelines on prevention of acute chemotherapy-induced nausea and vomiting in pediatric patients. Pediatr Blood Cancer. 2023, 70:e30210. 10.1002\/pbc.30210","journal-title":"Pediatr Blood Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08342-1","article-title":"The effectiveness of NEPA in the prevention of chemotherapy-induced nausea vomiting among chemo naive patients in an Indian setting","volume":"21","author":"Vaswani B","year":"2021","unstructured":"Vaswani B, Dattatreya PS, Bhagat S, Patil S, Barkate H. The effectiveness of NEPA in the prevention of chemotherapy-induced nausea vomiting among chemo naive patients in an Indian setting. BMC Cancer. 2021, 21:601. 10.1186\/s12885-021-08342-1","journal-title":"BMC Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu110","article-title":"Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study","volume":"25","author":"Hesketh PJ","year":"2014","unstructured":"Hesketh PJ, Rossi G, Rizzi G, et al.. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol. 2014, 25:1340-6. 10.1093\/annonc\/mdu110","journal-title":"Ann Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11433","article-title":"Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America","volume":"97","author":"Poli-Bigelli S","year":"2003","unstructured":"Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al.. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003, 97:3090-8. 10.1002\/cncr.11433","journal-title":"Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2091","article-title":"Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studies","volume":"8","author":"Schwartzberg L","year":"2019","unstructured":"Schwartzberg L, Karthaus M, Rossi G, et al.. Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studies. Cancer Med. 2019, 8:2064-73. 10.1002\/cam4.2091","journal-title":"Cancer Med"},{"key":"ref10","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Antiemesis. Version 2. (2021). https:\/\/www.nccn.org\/guidelines\/recently-published-guidelines."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159\/000514891","article-title":"Quality of life effects of an oral fixed combination of netupitant and palonosetron in chemotherapy-induced nausea and vomiting prevention: real-world evidence in patients with breast cancer receiving anthracycline-cyclophosphamide-based chemotherapy","volume":"17","author":"Schilling J","year":"2022","unstructured":"Schilling J, Kurbacher CM, Hanusch C, et al.. Quality of life effects of an oral fixed combination of netupitant and palonosetron in chemotherapy-induced nausea and vomiting prevention: real-world evidence in patients with breast cancer receiving anthracycline-cyclophosphamide-based chemotherapy. Breast Care (Basel). 2022, 17:130-6. 10.1159\/000514891","journal-title":"Breast Care (Basel)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1515442","article-title":"Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting","volume":"374","author":"Navari RM","year":"2016","unstructured":"Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med. 2016, 374:1356-67. 10.1056\/NEJMra1515442","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3313-0","article-title":"2016 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy","volume":"25","author":"Herrstedt J","year":"2017","unstructured":"Herrstedt J, Roila F, Warr D, et al.. 2016 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy. Support Care Cancer. 2017, 25:277-88. 10.1007\/s00520-016-3313-0","journal-title":"Support Care Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds021","article-title":"The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)","volume":"23","author":"Aapro M","year":"2012","unstructured":"Aapro M, Molassiotis A, Dicato M, et al.. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol. 2012, 23:1986-92. 10.1093\/annonc\/mds021","journal-title":"Ann Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.8123","article-title":"Prevention of delayed nausea: a university of Rochester cancer Center Community clinical oncology program study of patients receiving chemotherapy","volume":"30","author":"Roscoe JA","year":"2012","unstructured":"Roscoe JA, Heckler CE, Morrow GR, Mohile SG, Dakhil SR, Wade JL, Kuebler JP. Prevention of delayed nausea: a university of Rochester cancer Center Community clinical oncology program study of patients receiving chemotherapy. J Clin Oncol. 2012, 30:3389-95. 10.1200\/JCO.2011.39.8123","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(15)00035-2","article-title":"Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials","volume":"16","author":"Rapoport BL","year":"2015","unstructured":"Rapoport BL, Chasen MR, Gridelli C, et al.. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol. 2015, 16:1079-89. 10.1016\/s1470-2045(15)00035-2","journal-title":"Lancet Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S47790","article-title":"Sleeping well with cancer: a systematic review of cognitive behavioral therapy for insomnia in cancer patients","volume":"10","author":"Garland SN","year":"2014","unstructured":"Garland SN, Johnson JA, Savard J, Gehrman P, Perlis M, Carlson L, Campbell T. Sleeping well with cancer: a systematic review of cognitive behavioral therapy for insomnia in cancer patients. Neuropsychiatr Dis Treat. 2014, 10:1113-24. 10.2147\/NDT.S47790","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu096","article-title":"A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy","volume":"25","author":"Gralla RJ","year":"2014","unstructured":"Gralla RJ, Bosnjak SM, Hontsa A, et al.. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol. 2014, 25:1333-9. 10.1093\/annonc\/mdu096","journal-title":"Ann Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-8049(11)71080-2","article-title":"POSTER DISCUSSION the effect of guideline consistent antiemetic prophylaxis on chemotherapy-induced nausea and vomiting (CINV) in the overall, acute, and delayed phases: The pan European Emesis registry (PEER)","volume":"47","author":"Aapro M","year":"2011","unstructured":"Aapro M, Molassiotis A, Dicato M, Gascon P, Ma L, Burke T, Roila F. 3007: POSTER DISCUSSION the effect of guideline consistent antiemetic prophylaxis on chemotherapy-induced nausea and vomiting (CINV) in the overall, acute, and delayed phases: The pan European Emesis registry (PEER). Eur J Cancer. 2011, 47:224. 10.1016\/s0959-8049(11)71080-2","journal-title":"Eur J Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/287021-dexamethasone-sparing-antiemetic-prophylaxis-for-chemotherapy-induced-nausea-and-vomiting-in-highly-and-moderately-emetogenic-chemotherapy-the-sheild-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T05:40:45Z","timestamp":1727415645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/287021-dexamethasone-sparing-antiemetic-prophylaxis-for-chemotherapy-induced-nausea-and-vomiting-in-highly-and-moderately-emetogenic-chemotherapy-the-sheild-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,26]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.70290","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,26]]}}}